MRZM Stock Chart & Stats
$0.05
<$0.01(2.13%)
At close: 4:00 PM EST
$0.05
<$0.01(2.13%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume435.00
Average Volume (3M)112.00
Market Cap
$132.00
Enterprise Value$20.65M
Total Cash (Recent Filing)$63.73K
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)―
Beta9.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding131,793,090
10 Day Avg. Volume338
30 Day Avg. Volume112
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.98
Price to Sales (P/S)7.04
P/FCF Ratio-0.97
Enterprise Value/Market Cap156.43K
Enterprise Value/Revenue112.58
Enterprise Value/Gross Profit-28.04
Enterprise Value/Ebitda-1.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Marizyme News
MRZM FAQ
What was Marizyme Incorporated’s price range in the past 12 months?
Marizyme Incorporated lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Marizyme Incorporated’s market cap?
Marizyme Incorporated’s market cap is $132.00.
When is Marizyme Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Marizyme Incorporated’s earnings last quarter?
Currently, no data Available
Is Marizyme Incorporated overvalued?
According to Wall Street analysts Marizyme Incorporated’s price is currently Overvalued.
Does Marizyme Incorporated pay dividends?
Marizyme Incorporated does not currently pay dividends.
What is Marizyme Incorporated’s EPS estimate?
Marizyme Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marizyme Incorporated have?
Marizyme Incorporated has 131,793,090 shares outstanding.
What happened to Marizyme Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Marizyme Incorporated?
Currently, no hedge funds are holding shares in MRZM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marizyme Incorporated
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.